clinical trial · NCT06209580
AMT-253 in Patients With Advanced Solid Tumours
Malignant MelanomaAdvanced Solid TumorsAMT-253 for injection
brief summary
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
started
Jan 31, 2024
primary completion
Apr 30, 2026
completion
Dec 31, 2026
last updated
Sep 5, 2025
official title
Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol